Description
This blend contains two synthetic peptides: CJC-1295 without DAC (also called Modified GRF 1-29) and Ipamorelin. CJC-1295 without DAC (5mg) is a 29-amino-acid peptide analog of growth hormone-releasing hormone (GHRH). It was developed by modifying four amino acids in the native GHRH(1-29) sequence to increase resistance to enzymatic breakdown. Its molecular formula is C₁₅₂H₂₅₂N₄₄O₄₂ with a molecular weight of approximately 3367 g/mol. Ipamorelin (5mg) is a pentapeptide — five amino acids — with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ and a molecular weight of approximately 711.86 g/mol. It was first described in 1998.
The blend totals 10mg in a 1:1 ratio, supplied as a white lyophilized powder that dissolves readily in water. Store refrigerated at 2–8 °C. This product is strictly for research purposes only.
PubChem Reference: View compound profile on NIH PubChem
This product is strictly for research purposes only. Not approved for human or animal use.
Blend Composition
PEPTIDE COMPONENTS
CJC-1295 no DAC: 5mg (Modified GRF 1-29)
Ipamorelin: 5mg (Pentapeptide)
Total Peptide: 10mg
Ratio: 1:1 Equal blend
PHYSICAL PROPERTIES
Form: White lyophilized powder
Solubility: Readily dissolves in water
Stability: Enhanced compared to native GHRH
Storage: Keep refrigerated 36‑46 °F (2‑8 °C)
Why CJC-1295 and Ipamorelin Are Paired
The GHRH-receptor/ghrelin-receptor combination is one of the more mechanistically well-reasoned pairings in peptide research, since the two pathways converge on GH release through independent signaling routes. Published pharmacology on Ipamorelin specifically highlights its receptor selectivity as the reason it’s preferred in combination protocols over older ghrelin-mimetic peptides, which tend to produce larger cortisol and prolactin spikes alongside GH release.
Frequently Asked Questions :
Why combine CJC-1295 and Ipamorelin?
They act on different receptors, GHRH receptor and ghrelin receptor, for additive GH release research with a cleaner secondary hormone profile than older GHRPs.
What makes Ipamorelin different from GHRP-6 or GHRP-2?
Its selectivity, research shows it stimulates GH release without significantly raising cortisol, prolactin, or appetite.
What is CJC-1295 “without DAC”?
A shorter-acting version (Mod GRF 1-29) without the Drug Affinity Complex that extends half-life, closer to native GHRH clearance kinetics.
How should the blend be reconstituted and stored?
Bacteriostatic water, refrigerate 2–8°C.
Where can I buy this blend for research?
10mg kit, HPLC/MS verified.
Prof. Jenna L. Whitmore –
Very reliable blend. Both peptides maintained stability in solution for 48 hours at 4°C. The synergy between CJC-1295 noDAC and Ipamorelin was evident in our cell-based assays. Would give 5 stars if the blend ratio was specified on the label
Prof. Simone L. Durant –
Well-balanced blend for research on growth hormone secretagogues. The noDAC version of CJC-1295 paired with Ipamorelin gave us a clear pulsatile profile without prolonged receptor desensitization. Shipping to France was smooth
Dr. Nathan R. Ellsworth –
The combination of CJC-1295 noDAC and Ipamorelin works synergistically in our in vitro GH release assays. Both CAS identifiers (863288-34-0 and 170851-70-4) were verified. Clean 99% purity and easy reconstitution
Dr. Omar K. Siddiqui –
Consistent activity across multiple vials. The 99% purity claim held up under our HPLC analysis. Ideal for studies requiring dual GHRH and ghrelin receptor pathway activation. Highly recommend for preclinical work.